Literature DB >> 33887359

Falls are common, morbid, and predictable in patients with cirrhosis.

Elliot B Tapper1, Samantha Nikirk2, Neehar D Parikh2, Lilli Zhao3.   

Abstract

BACKGROUND & AIMS: Falls are a devastating complication of cirrhosis. The risk of falls in patients without hepatic encephalopathy (HE) is unclear. Further, bedside tools for predicting falls are lacking. Thus, we aimed to internally validate a predictive model for falls and evaluate the association between incident falls and mortality.
METHODS: We prospectively enrolled 299 patients with currently compensated Child A-B (70% Child-Pugh A) cirrhosis and portal hypertension without prior HE from 7/2016-8/2018. We followed patients for a median of 1,003 days (IQR 640-1,102) for incident falls accounting for the competing risk of death or transplantation. Candidate baseline fall predictors included patient-reported outcomes (e.g. Short-Form-8), physical function (e.g. chair-stands), blood tests (e.g. model for end-stage liver disease-sodium [MELD-Na] and its components), and cognitive function (using inhibitory control testing).
RESULTS: During follow-up: 141 (47%) patients experienced falls, with 38 (13%) sustaining injuries, 49 (16%) died and 13 (4%) received transplants. Median time to a fall was 279 (98-595) days. The overall probability of falls was 28.8% and 50.2% at years 1 and 3; the probability of injurious falls was 9.1% and 16.5%, respectively. We derived a predictive model for falls. The FallSSS score (prior falls, chair-stands, sodium, and SF-8) had an AUROC for injurious falls at 6- and 12-months of 0.79 and 0.81, while MELD-Na's AUROC was 0.57 for both. Adjusting for baseline Child-Pugh class, MELD-Na, albumin level, disability status, and comorbidities, both incident falls (subdistribution hazard ratio [sHR] 2.76; 95% CI 1.46-5.24) and HE (sHR 4.25; 95% CI 2.15-8.41) were strongly and independently associated with mortality.
CONCLUSION: Our prospective study of patients with cirrhosis without a baseline history of HE demonstrates that falls are common, morbid, and predictable. These data highlight both the value of expanding screening to patients with cirrhosis and the potential for benefit in studies of interventions to address fall-risk in this vulnerable population. LAY
SUMMARY: Falls are a devastating complication of cirrhosis. Bedside tools for predicting falls are lacking. We found that falls were very common and often associated with serious injuries. Falls were also associated with an increased risk of death. Falls could be predicted with an algorithm called FallSSS - based on prior history of falls, blood sodium level, number of chair-stands performed in 30 seconds, and quality of life.
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Frailty; MELD; ascites; patient-reported outcomes

Mesh:

Year:  2021        PMID: 33887359      PMCID: PMC8380639          DOI: 10.1016/j.jhep.2021.04.012

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   30.083


  32 in total

1.  Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks.

Authors:  Paul Blanche; Jean-François Dartigues; Hélène Jacqmin-Gadda
Journal:  Stat Med       Date:  2013-09-12       Impact factor: 2.373

2.  Psychoactive Medications Increase the Risk of Falls and Fall-related Injuries in Hospitalized Patients With Cirrhosis.

Authors:  Elliot B Tapper; Yesenia Risech-Neyman; Neil Sengupta
Journal:  Clin Gastroenterol Hepatol       Date:  2015-03-26       Impact factor: 11.382

3.  Development of a novel frailty index to predict mortality in patients with end-stage liver disease.

Authors:  Jennifer C Lai; Kenneth E Covinsky; Jennifer L Dodge; W John Boscardin; Dorry L Segev; John P Roberts; Sandy Feng
Journal:  Hepatology       Date:  2017-06-28       Impact factor: 17.425

4.  Performance-Based Measures Associate With Frailty in Patients With End-Stage Liver Disease.

Authors:  Jennifer C Lai; Michael L Volk; Debra Strasburg; Neil Alexander
Journal:  Transplantation       Date:  2016-12       Impact factor: 4.939

Review 5.  Patient-reported outcomes in cirrhosis: A scoping review of the literature.

Authors:  Elliot B Tapper; Fasiha Kanwal; Sumeet K Asrani; Chanda Ho; Nadia Ovchinsky; John Poterucha; Avegail Flores; Judith E Smith; Victor Ankoma-Sey; Bruce Luxon; Michael L Volk
Journal:  Hepatology       Date:  2018-04-19       Impact factor: 17.425

6.  Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests.

Authors:  Elliot B Tapper; Neehar D Parikh; Akbar K Waljee; Michael Volk; Noelle E Carlozzi; Anna S-F Lok
Journal:  Am J Gastroenterol       Date:  2018-03-13       Impact factor: 10.864

7.  Regularization Paths for Generalized Linear Models via Coordinate Descent.

Authors:  Jerome Friedman; Trevor Hastie; Rob Tibshirani
Journal:  J Stat Softw       Date:  2010       Impact factor: 6.440

8.  Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis.

Authors:  Vishwadeep Ahluwalia; James B Wade; Leroy Thacker; Kenneth A Kraft; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Iliana Bouneva; Puneet Puri; Velimir Luketic; Arun J Sanyal; Hochong Gilles; Douglas M Heuman; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2013-05-07       Impact factor: 25.083

9.  Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patient-Reported Outcomes in Cirrhosis.

Authors:  Elliot B Tapper; Jad Baki; Neehar D Parikh; Anna S Lok
Journal:  Hepatology       Date:  2019-02-19       Impact factor: 17.425

10.  Bedside Measures of Frailty and Cognitive Function Correlate with Sarcopenia in Patients with Cirrhosis.

Authors:  Elliot B Tapper; Brian Derstine; Jad Baki; Grace L Su
Journal:  Dig Dis Sci       Date:  2019-07-10       Impact factor: 3.199

View more
  8 in total

Review 1.  Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy.

Authors:  Jeremy Louissaint; Sasha Deutsch-Link; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2022-08       Impact factor: 13.576

2.  Portal vein thrombosis is associated with an increased risk of bone fractures.

Authors:  Simon Johannes Gairing; Peter Robert Galle; Jörn Markus Schattenberg; Karel Kostev; Christian Labenz
Journal:  PLoS One       Date:  2022-04-22       Impact factor: 3.752

3.  The 5Ms of Geriatrics in Gastroenterology: The Path to Creating Age-Friendly Care for Older Adults With Inflammatory Bowel Diseases and Cirrhosis.

Authors:  Bharati Kochar; Nneka N Ufere; Christine S Ritchie; Jennifer C Lai
Journal:  Clin Transl Gastroenterol       Date:  2022-01-12       Impact factor: 4.396

4.  Deprescribing zolpidem reduces falls and fractures in patients with cirrhosis.

Authors:  Elliot B Tapper; Zhe Zhao; G Scott Winder; Neehar D Parikh
Journal:  JHEP Rep       Date:  2022-03-25

5.  Incidence and Risk Factors for Cerebrovascular-Specific Mortality in Patients with Colorectal Cancer: A Registry-Based Cohort Study Involving 563,298 Patients.

Authors:  Zhi-Hui Dai; Ming Tang; Yun-Liang Chen; Tao-Lan Zhang; Jing Li; Guo-Hua Lv; Yi-Guo Yan; Zhi-Hua Ouyang; Wei Huang; Ming-Xiang Zou
Journal:  Cancers (Basel)       Date:  2022-04-19       Impact factor: 6.639

Review 6.  Review article: current and emerging therapies for the management of cirrhosis and its complications.

Authors:  Elliot B Tapper; Nneka N Ufere; Daniel Q Huang; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2022-03-02       Impact factor: 9.524

7.  Cognitive Impairment and Cirrhosis in Older Patients: A Systematic Review.

Authors:  Kabiru Ohikere; Nicolette Veracruz; Robert J Wong
Journal:  Gerontol Geriatr Med       Date:  2022-09-09

8.  Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jennifer C Lai; Puneeta Tandon; William Bernal; Elliot B Tapper; Udeme Ekong; Srinivasan Dasarathy; Elizabeth J Carey
Journal:  Hepatology       Date:  2021-09       Impact factor: 17.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.